Is the CSL Limited share price still in the buy zone?

Credit: US Army RDECOM

Much to the delight of its shareholders, the CSL Limited (ASX: CSL) share price has been one of the best performers on the market this year.

Year-to-date the biotherapeutics company’s shares have put on a gain of over 37%.

Can the run continue?

While I think CSL’s run can continue, I do think it is approaching fair value now so the upside potential for its shares may be somewhat limited in the short-term.

After all, based on its FY 2018 forecast for net profit after tax in the range of US$1,480 million to US$1,550 million, I estimate that CSL’s shares are changing hands at approximately 31x forward earnings.

But that doesn’t mean you shouldn’t invest today. In my opinion CSL is up there with Ramsay Health Care Limited (ASX: RHC) as one of the highest quality companies in Australia and a great long-term buy and hold investment option.

That’s because with demand for its immunoglobulin and specialty products growing strongly, its fledgling Seqirus influenza business close to being profitable, and margins expanding, I feel CSL could deliver above-average earnings growth for the next decade.

All in all, I believe this puts CSL’s shares in a strong position to outperform the local share market over the next ten years.

Just like they did over the previous ten years when they provided an average annual total return of 16.3% per annum.

As well as CSL, I think these top shares could be great buy and hold investment options.

Top 3 ASX Blue Chips To Buy In 2017

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool's in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool's Top 3 Blue Chip Stocks for 2017."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand - and how quickly the share prices of these companies moves - we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.